Document is current
Any future updates will be listed below
-
Authors
Nakagaki, Hidetaka
Yamauchi, Takuji
Mukaino, Takahiko
Sakata, Ayumi
Watanabe, Eriko
Watanabe, Mitsuru
Ishihara, Daisuke
Imanaga, Hiroshi https://orcid.org/0000-0003-1012-2311
Sasaki, Kensuke
Sakoda, Teppei
Jinnouchi, Fumiaki
Miyawaki, Kohta
Shima, Takahiro
Kikushige, Yoshikane https://orcid.org/0000-0002-7721-1696
Mori, Yasuo
Hotta, Taeko
Kunisaki, Yuya https://orcid.org/0000-0003-0141-7038
Shigeto, Hiroshi
Isobe, Noriko
Akashi, Koichi
Kato, Koji
- License Information
-
More Information
Article History
Received: 22 February 2025
Revised: 14 April 2025
Accepted: 17 April 2025
First Online: 28 April 2025
Competing interests
: KK; Honoraria: AbbVie, Bristol-Myers Squibb, Chugai, Dainippon-Sumitomo, Janssen, Kyowa Kirin, MSD, AbbVie, Ono, Gilead Sciences, Novartis; Consulting or Advisory Role: AbbVie, AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Janssen, Bristol-Myers Squibb, Novartis, Gilead Sciences; Research Funding: AbbVie, Astellas, MSD, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, Novartis, Ono, Gilead Sciences.
: This study was approved by the Institutional Review Board of Kyushu University. All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all participants.
